CLINICAL TRIALS PROFILE FOR ROXICODONE
✉ Email this page to a colleague
All Clinical Trials for ROXICODONE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00726830 ↗ | Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer | Terminated | National Cancer Institute (NCI) | N/A | 2009-03-01 | RATIONALE: Methadone, morphine, or oxycodone may help relieve pain caused by cancer. It is not yet known whether methadone is more effective than morphine or oxycodone in treating pain in patients with cancer. PURPOSE: This randomized clinical trial is studying methadone to see how well it works compared with morphine or oxycodone in treating pain in patients with cancer. |
NCT00726830 ↗ | Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer | Terminated | M.D. Anderson Cancer Center | N/A | 2009-03-01 | RATIONALE: Methadone, morphine, or oxycodone may help relieve pain caused by cancer. It is not yet known whether methadone is more effective than morphine or oxycodone in treating pain in patients with cancer. PURPOSE: This randomized clinical trial is studying methadone to see how well it works compared with morphine or oxycodone in treating pain in patients with cancer. |
NCT00853216 ↗ | Fasting Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets | Completed | Mallinckrodt | Phase 1 | 2003-01-01 | The objective of this open-label, randomized, two-period crossover study was to compare the oral bioavailability of a Mallinckrodt test tablet formulation of oxycodone 30 mg to an equivalent oral dose of a commercially available oxycodone tablet (Roxicodone™ 30 mg, Roxane Laboratories, Inc.) in a test group of healthy subjects under fasting conditions. |
NCT00853320 ↗ | Fasting Study of Oxycodone Hydrochloride 15 mg Tablets and Roxicodone™ 15 mg Tablets | Completed | Mallinckrodt | Phase 1 | 2003-02-01 | The objective of this open-label, randomized, two-period crossover study was to compare the oral bioavailability of a Mallinckrodt test tablet formulation of oxycodone 15 mg to an equivalent oral dose of a commercially available oxycodone tablet (Roxicodone™ 15 mg, Roxane Laboratories, Inc.) in a test group of healthy subjects under fasting conditions. |
NCT00853736 ↗ | Fed Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets | Completed | Mallinckrodt | Phase 1 | 2003-02-01 | The objective of this open-label, randomized, two-period crossover study was to compare the oral bioavailability of a Mallinckrodt test tablet formulation of oxycodone 30 mg to an equivalent oral dose of a commercially available oxycodone tablet (Roxicodone™ 30 mg, Roxane Laboratories, Inc.) in a test group of healthy subjects under fed conditions. |
NCT00978328 ↗ | Oxycodone User Registry (OUR) | Completed | Ortho-McNeil Janssen Scientific Affairs, LLC | 2009-06-01 | The purpose of this study is to describe clinical and demographic characteristics of patients receiving prescription medications containing oxycodone immediate release (OXYRX), to characterize patient and prescriber perceptions of the effectiveness outcomes and tolerability of OXYRX treatment, to describe prescriber decision-making about pain management with a Schedule II opioid and to explore how prescribers identify suspected abuse of pain medications. | |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ROXICODONE
Condition Name
Clinical Trial Locations for ROXICODONE
Trials by Country
Clinical Trial Progress for ROXICODONE
Clinical Trial Phase
Clinical Trial Sponsors for ROXICODONE
Sponsor Name